Sign in

Research summary ·

The Efficacy of Different Treatment Options in Cutaneous Sarcoidosis: A Meta-analysis of RCTs.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This review looked at drug treatments for sarcoidosis of the skin. This skin disease can lower quality of life. The team searched for trials in adults up to January 2025. In each trial, people were given either a drug or a placebo by chance. The team pooled the results from trials with 156 people in total.

What they found

The drugs did not clearly help the skin more than placebo. There was a hint of better quality of life with the drugs. But this result could still be due to chance. Serious side effects were about the same in both groups. The trials had a moderate to high risk of bias. Results varied little between the trials.

What it means for patients

The authors say add-on drugs did not clearly work better than steroids alone. They also say these drugs may still improve quality of life. Serious side effects did not seem to differ from placebo. The authors say bigger and better trials are needed.

Why it is not certain yet

All the trials together had 156 people. The authors say larger trials are needed. Risk of bias in the trials was moderate to high. The quality of life gain did not reach clear proof. A review can only be as good as the studies in it.

Source

The Efficacy of Different Treatment Options in Cutaneous Sarcoidosis: A Meta-analysis of RCTs.

PubMed · PMID 42708647

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Sarcoidosis publications